|
ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES") |
|||||
|
|
|||||
|
COMPANY NAME: |
|||||
|
International Brand Licensing plc (to be renamed EKF Diagnostics Holdings plc) |
|||||
|
COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) : |
|||||
|
14 Kinnerton Place South, London SW1X 8EH |
|||||
|
COUNTRY OF INCORPORATION: |
|||||
|
England and Wales
|
|||||
|
COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26: |
|||||
|
www.iblplc.com
|
|||||
|
COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED: |
|||||
|
The Admission is the result of a reverse takeover through the acquisition by International Brand Licensing plc of EKF-diagnostic GmbH ("EKF").
The existing business of International Brand Licensing plc is focused on exploiting a portfolio of sports and lifestyle brands, trade names and logos by granting licences to third parties allowing them to manufacture, market and sell products in pre determined territories across the world. The Directors intend to dispose of the company's licensing business as opportunities arise over the coming months.
The EKF Group comprises established businesses with operations in Germany, Poland and Russia which are focused on the design, development, manufacture and selling of diagnostic instruments and reagents. EKF's products and devices are designed to meet the needs of smaller professional clinical and research laboratories, doctor's offices, sports clinics and athletic testing sites.
|
|||||
|
DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares): |
|||||
|
A total of 100,435,653 new ordinary shares of 1 pence each and re admission of 41,991,653 existng ordinary shares of 1 pence each
The shares are expected to be admitted on three separate dates:
First admission (first tranche placing shares): 10,666,665 new ordinary shares of 1 pence each
Second admission (second tranche placing shares): 25,499,998 new ordinary shares of 1 pence each
Third admission (third tranche placing shares and re admission of existing ordinary shares): 64,268,990 new ordinary shares of 1 pence each and re admission of all existing ordinary shares
|
|||||
|
CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION: |
|||||
|
£ 15.06 million
Market Capitalisation expected to be £21.36 million on Admission
|
|||||
|
PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION: |
|||||
|
29.94%
|
|||||
|
DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM COMPANY HAS APPLIED OR AGREED TO HAVE ANY OF ITS SECURITIES (INCLUDING ITS AIM SECURITIES) ADMITTED OR TRADED: |
|||||
|
N/a
|
|||||
|
FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known): |
|||||
|
Directors David Eric Evans (Non-Executive Chairman) Julian Huw Baines (Chief Executive Officer) Paul Andrew Peter Foulger (Finance Director) Adam Reynolds (Non-Executive Director) Gordon James Hall (Non-Executive Director) Dr Kevin William Wilson (Non-Executive Director) |
|||||
|
FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known): |
|||||
|
|||||
|
NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: |
|||||
|
N/a
|
|||||
|
(i) ANTICIPATED ACCOUNTING REFERENCE DATE (ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information) (iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19: |
|||||
|
(i) 31 December (ii) 31 December 2009 (in relation to EKF); financial information in relation to International Brand Licensing plc has been omitted in accordance with Rule 28 (iii) 30 September 2010, 30 June 2011, 30 September 2011
|
|||||
|
EXPECTED ADMISSION DATE: |
|||||
|
7 July 2010
|
|||||
|
NAME AND ADDRESS OF NOMINATED ADVISER: |
|||||
|
Zeus Capital Limited
|
|||||
|
NAME AND ADDRESS OF BROKER: |
|||||
|
Joint Brokers: Zeus Capital Limited
Matrix Corporate Capital LLP One Vine Street London W1J 0AH
|
|||||
|
OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: |
|||||
|
www.iblplc.com The admission document contains full details about the company and the admission of its securities. |
|||||
|
DATE OF NOTIFICATION: |
|||||
|
18 June 2010
|
|||||
|
NEW/ UPDATE: |
|||||
|
New
|